Literature DB >> 23832290

A study on the association of autoantibodies, chemokine, and its receptor with disease activity in systemic lupus erythematosus in North Indian population.

Leishangthem Bidyalaxmi Devi1, Archana Bhatnagar, Ajay Wanchu, Aman Sharma.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic and complex autoimmune disease characterized by the production of autoantibodies against a spectrum of nuclear antigens. RANTES and its receptor CCR5 have been associated with the pathogenesis of SLE. The objective of this study is to analyze autoantibodies (DNA/RNA), allelic distribution of RANTES and the association of levels of RANTES and its receptor CCR5 in SLE patients in North Indian region. The RANTES-403 and RANTES-28 polymorphism in the promoter region of RANTES gene was studied in 80 patients and 80 healthy controls. The levels of chemokine RANTES, its receptor CCR5, anti-dsDNA, and anti-SSA antibodies levels were determined. Disease activity was assessed with the systemic lupus erythematosus disease activity index (SLEDAI) score. All the parameters were studied for statistical analysis by using t test (graph pad prism) and correlation by SPSS data. PCR-RFLP performed showed 28C/C and the 403G/G genotypes in both patients and controls, but no other genotypes such as 28C/G, 28G/G and 403A/G, 403A/A were found. Patients had higher levels of RANTES (1840.48 ± 739.42 vs. 835.44 ± 70.48 pg/ml; P < 0.0001) and its receptor CCR5 expression (26.49 ± 0.16 vs. 24.72 ± 3.02 %; P < 0.05) compared to controls. The levels of autoantibodies anti-dsDNA and anti-SSA were also higher in patients than controls. The patients showing elevated anti-dsDNA had negative correlation with SLEDAI score (P < 0.05) while borderline patients were not found to be correlated. In case of anti-Ro/anti-SSA antibody levels, the borderline patients showed a moderately significant negative correlation as compared to controls than patients with elevated autoantibody (P < 0.01). The levels of RANTES and CCR5 were also higher in case of patients than controls. But there was no significant correlation of RANTES and CCR5 with disease activity. We were unable to find an association of RANTES polymorphism with SLE in North Indian population in our sample. No significant difference in allele distribution of RANTES-28 and RANTES-403 in the sample of 160 individuals was detected. Of the two autoantibodies studied, anti-Ro/anti-SSA levels in borderline lupus patients appeared as an important parameter for monitoring/diagnosis of lupus patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23832290     DOI: 10.1007/s00296-013-2812-2

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  33 in total

1.  Fine mapping of the SLEB2 locus involved in susceptibility to systemic lupus erythematosus.

Authors:  V Magnusson; A K Lindqvist; C Castillejo-López; H Kristjánsdottir; K Steinsson; G Gröndal; G Sturfelt; L Truedsson; E Svenungsson; I Lundberg; I Gunnarsson; A I Bolstad; H J Haga; R Jonsson; L Klareskog; J Alcocer-Varela; D Alarcón-Segovia; J D Terwilliger; U B Gyllensten; M E Alarcón-Riquelme
Journal:  Genomics       Date:  2000-12-15       Impact factor: 5.736

2.  Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare.

Authors:  S Tian; J Li; L Wang; T Liu; H Liu; G Cheng; D Liu; Y Deng; R Gou; Y Wan; J Jia; C Chen
Journal:  Inflamm Res       Date:  2007-07       Impact factor: 4.575

Review 3.  Pathogenicity and proteomic signatures of autoantibodies to Ro and La.

Authors:  Rhianna Lindop; Georgia Arentz; Lauren A Thurgood; Joanne H Reed; Michael W Jackson; Tom P Gordon
Journal:  Immunol Cell Biol       Date:  2012-01-17       Impact factor: 5.126

4.  Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  Dilip Shah; Ajay Wanchu; Archana Bhatnagar
Journal:  Immunobiology       Date:  2011-04-13       Impact factor: 3.144

5.  Increased serum RANTES in patients with systemic lupus erythematosus.

Authors:  Man-Man Lu; Juan Wang; Hai-Feng Pan; Gui-Mei Chen; Jing Li; Han Cen; Chen-Chen Feng; Dong-Qing Ye
Journal:  Rheumatol Int       Date:  2011-01-22       Impact factor: 2.631

6.  Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus.

Authors:  C Eriksson; K Eneslätt; J Ivanoff; S Rantapää-Dahlqvist; K G Sundqvist
Journal:  Lupus       Date:  2003       Impact factor: 2.911

7.  Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus.

Authors:  Francisco Aguilar; Antonio Núñez-Roldán; Belén Torres; Ingeborg Wichmann; Julio Sánchez-Román; Maria Francisca González-Escribano
Journal:  J Rheumatol       Date:  2003-08       Impact factor: 4.666

8.  The role of T helper cell subsets in pathogenesis of Systemic Lupus Erythematosus and their relation to disease activity.

Authors:  Jamal Al-Saleh; Sabrine el-Eissawy
Journal:  Egypt J Immunol       Date:  2006

9.  Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus.

Authors:  Adla B Hassan; Ingrid E Lundberg; David Isenberg; Marie Wahren-Herlenius
Journal:  Scand J Rheumatol       Date:  2002       Impact factor: 3.641

10.  Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils.

Authors:  Y Kameyoshi; A Dörschner; A I Mallet; E Christophers; J M Schröder
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

View more
  2 in total

1.  Chemokine receptor 5 Δ32 polymorphism and systemic lupus erythematosus, vasculitis, and primary Sjogren's syndrome. Meta-analysis of possible associations.

Authors:  Y H Lee; J-H Kim; G G Song
Journal:  Z Rheumatol       Date:  2014-11       Impact factor: 1.372

Review 2.  Gq-Coupled Receptors in Autoimmunity.

Authors:  Lu Zhang; Guixiu Shi
Journal:  J Immunol Res       Date:  2016-01-17       Impact factor: 4.818

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.